Phase I Targeted Combination Trial of Sorafenib and GW5074 in Patients with Advanced Refractory Solid Tumors

Background: Combination therapy with the administration of GW5074 and sorafenib significantly induced necrotic death in various cancer cells in vivo, as well as prolonging the survival of an animal disease model due to significant suppression of the primary and metastatic lesions. We sought to deter...

Descripción completa

Detalles Bibliográficos
Autores principales: Kao, Chien-Chang, Ho, Ching-Liang, Yang, Ming-Hsin, Tsai, Yi-Ta, Liu, Shu-Yu, Chang, Ping-Ying, Wu, Yi-Ying, Chen, Jia-Hong, Huang, Tzu-Chuan, Yehn, Ren-Hua, Dai, Ming-Shen, Chen, Yeu-Chin, Sun, Guang-Huan, Cha, Tai-Lung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9031611/
https://www.ncbi.nlm.nih.gov/pubmed/35456276
http://dx.doi.org/10.3390/jcm11082183

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9031611/
https://www.ncbi.nlm.nih.gov/pubmed/35456276
http://dx.doi.org/10.3390/jcm11082183

Ejemplares similares